Diabetology Xagena

Xagena Mappa
Medical Meeting
Onco News

Search results for "Semaglutide"

The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The trial investigated the efficacy and safety of 0.5 mg and 1.0 m ...

Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at the American Diabetes Association ( ADA ) 76th Scientific S ...

The results from PIONEER 8, a phase 3a trial with oral Semaglutide ( Ozempic ) for the treatment of adults with type 2 diabetes. Oral Semaglutide is an investigational GLP-1 analogue taken once dail ...